J G Frelinger
Overview
Explore the profile of J G Frelinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1070
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Martin B, Frelinger J, Ting J
J Immunol
. 1999 Jun;
162(11):6663-70.
PMID: 10352284
Early reports suggest that the costimulatory molecule CD86 (B7-2) has sporadic efficacy in tumor immunity, whereas changes in cancer immunity mediated by the MHC class II transactivator (CIITA) have not...
12.
Ostberg J, Barth R, Frelinger J
Immunol Today
. 1998 Dec;
19(12):546-50.
PMID: 9864944
No abstract available.
13.
Wei C, Callahan B, Turner M, WILLIS R, Lord E, Barth R, et al.
Int J Mol Med
. 1998 Dec;
2(4):487-96.
PMID: 9857240
The human prostate-specific antigen (PSA) and glandular kallikrein-1 (hGK-1, also known as hK2) genes are tandemly located on chromosome 19, separated by a 12-kb intergenic region. The coordinate regulation of...
14.
WILLIS R, Wei C, Turner M, Callahan B, Pugh A, Barth R, et al.
Int J Mol Med
. 1998 Dec;
1(2):379-86.
PMID: 9852240
Prostate-specific antigen (PSA) has been used clinically as a marker for the diagnosis and staging of prostate cancer due to its specific expression in prostate epithelial cells. In addition to...
15.
Yeh K, McAdam A, Pulaski B, Shastri N, Frelinger J, Lord E
J Immunol
. 1998 Jun;
160(12):5773-80.
PMID: 9637487
Recent studies have reported that APC can present particulate exogenous Ag in the context of class I MHC to CD8+ CTL, and our laboratory demonstrated that IL-3 could enhance CTL...
16.
Lord E, Yeh K, Moran J, Storozynsky E, Frelinger J
J Immunother
. 1998 Jun;
21(3):205-10.
PMID: 9610912
Mice were exposed to interleukin- (IL-) 3 in vivo by injection of tumor cells transfected with the IL-3 gene. At 10 days post tumor injection, bone marrow cells were recovered,...
17.
Lord E, Frelinger J
Cancer Immunol Immunother
. 1998 Apr;
46(2):75-81.
PMID: 9558002
Increasing the ability of tumor-reactive T cells to mediate tumor regression in vivo has been a major goal of tumor immunologists. Progress toward this goal has been aided by the...
18.
Lee J, Fenton B, Koch C, Frelinger J, Lord E
Cancer Res
. 1998 Apr;
58(7):1478-85.
PMID: 9537251
Microenvironmental conditions within solid tumors can have marked effects on the growth of the tumors and their response to therapies. The disorganized growth of tumors and their attendant vascular systems...
19.
Ostberg J, Dragone L, Borrello M, Phipps R, Barth R, Frelinger J
Eur J Immunol
. 1997 Oct;
27(9):2152-9.
PMID: 9341753
CD43 (leukosialin), a sialylated glycoprotein expressed on the surface of most hematopoietic cells, has been implicated in cell adhesion and signaling. However, its precise physiological function remains unclear. We used...
20.
Wei C, WILLIS R, Tilton B, Looney R, Lord E, Barth R, et al.
Proc Natl Acad Sci U S A
. 1997 Jun;
94(12):6369-74.
PMID: 9177224
Human prostate-specific antigen (PSA) has been widely used as a serum marker for cancer of the prostate. The cell type-specific expression of PSA also makes it a potential tumor antigen...